Algatechnologies (Algatech), a global biotechnology company specialising in the commercial cultivation of microalgae, has appointed Ronnie Meninger as CEO.
Hagai Stadler, of Grovepoint (Algatech’s major shareholder), who for the last two years has been interim CEO, will join the Board of Directors and take charge of M&A activities at the company.
Sammy Boussiba has also been appointed Chief Scientist to Algatech’s Board of Directors.
Boussiba is among the world’s leading scientists in microalgae biotechnology and the inventor of the technology used by Algatech for the AstaPure natural astaxanthin production.
Meninger has more than 30 years of experience in the fine chemical, special ingredients and pharmaceutical industries. She has held multiple managerial positions, and was Managing Director of Chemada Fine Chemicals, Israel (part of the ICL Group). She also is a board member of several public companies in Israel.
‘I’m excited to join Algatech and be part of its excellent team,’ said Meninger. ‘Our strategy for the next years includes major investments in developing unique active ingredients, incorporating innovative technologies to our cultivating process and growing through synergistic acquisitions.
‘In addition, we will offer new delivery forms and increase our focus on compiling more comprehensive scientific data for the AstaPure brand in order to maintain our distinctive quality, and offer advanced natural astaxanthin solutions to our customers. We also will recruit new key positions and invest further in human resources.’
